Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Global Clinical Trials Review, H1, 2014

Summary

GlobalData's clinical trial report, “Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Global Clinical Trials Review, H1, 2014" provides data on the Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Mucopolysaccharidosis I (MPS I) (Hurler Syndrome). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Mucopolysaccharidosis I (MPS I) (Hurler Syndrome). This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table Of Contents

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) to Metabolic Disorders Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) to Metabolic Disorders Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials by Phase 20
In Progress Trials by Phase 21
Clinical Trials by Trial Status 22
Clinical Trials by End Point Status 23
Unaccomplished Trials of Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) 24
Subjects Recruited Over a Period of Time 26
Clinical Trials by Sponsor Type 27
Prominent Sponsors 28
Top Companies Participating in Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Clinical Trials 29
Prominent Drugs 30
Latest Clinical Trials News on Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) 31
Apr 20, 2012: Athersys Announces Publication Of Results Of Preclinical Study Of MultiStem In Cell Transplant 31
Clinical Trial Profiles 32
Clinical Trial Overview of Top Companies 32
Sanofi 32
Clinical Trial Overview of Sanofi 32
Medical Resources International Pte Ltd 33
Clinical Trial Overview of Medical Resources International Pte Ltd 33
Cytomedix, Inc. 34
Clinical Trial Overview of Cytomedix, Inc. 34
ArmaGen Technologies, Inc. 35
Clinical Trial Overview of ArmaGen Technologies, Inc. 35
Clinical Trial Overview of Top Institutes / Government 36
Masonic Cancer Center 36
Clinical Trial Overview of Masonic Cancer Center 36
University of Minnesota 37
Clinical Trial Overview of University of Minnesota 37
University of California, Los Angeles 38
Clinical Trial Overview of University of California, Los Angeles 38
New York Medical College 39
Clinical Trial Overview of New York Medical College 39
Tehran University of Medical Sciences 40
Clinical Trial Overview of Tehran University of Medical Sciences 40
Center for International Blood and Marrow Transplant Research 41
Clinical Trial Overview of Center for International Blood and Marrow Transplant Research 41
Erasmus MC 42
Clinical Trial Overview of Erasmus MC 42
The University of Chicago 43
Clinical Trial Overview of The University of Chicago 43
University of Louisville 44
Clinical Trial Overview of University of Louisville 44
Five Key Clinical Profiles 45
Appendix 72
Abbreviations 72
Definitions 72
Research Methodology 73
Secondary Research 73
About GlobalData 74
Contact Us 74
Disclaimer 74
Source 74

List of Tables
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics, Global, Clinical Trials by Region, 2014* 7
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2014* 10
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014* 13
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Clinical Trials, Central and South America, Top Countries, 2014* 14
Proportion of Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) to Metabolic Disorders Clinical Trials, G7 Countries (%), 2014* 15
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) to Metabolic Disorders Clinical Trials, E7 Countries (%), 2014* 18
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics, Global, Clinical Trials by Phase, 2014* 20
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 21
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics, Global, Clinical Trials by Trial Status, 2014* 22
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Clinical Trials, Global, by End Point Status, 2014* 23
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics, Global, Suspended Clinical Trials, 2014* 24
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics, Global, Terminated Clinical Trials, 2014* 25
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 26
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 27
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 28
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 29
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 30
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Clinical Trials Market, Global, Clinical Trials by Sanofi, 2014* 32
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Clinical Trials Market, Global, Clinical Trials by Medical Resources International Pte Ltd, 2014* 33
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Clinical Trials Market, Global, Clinical Trials by Cytomedix, Inc., 2014* 34
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Clinical Trials Market, Global, Clinical Trials by ArmaGen Technologies, Inc., 2014* 35
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Clinical Trials Market, Global, Clinical Trials by Masonic Cancer Center, 2014* 36
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Minnesota, 2014* 37
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Clinical Trials Market, Global, Clinical Trials by University of California, Los Angeles, 2014* 38
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Clinical Trials Market, Global, Clinical Trials by New York Medical College, 2014* 39
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Clinical Trials Market, Global, Clinical Trials by Tehran University of Medical Sciences, 2014* 40
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Clinical Trials Market, Global, Clinical Trials by Center for International Blood and Marrow Transplant Research, 2014* 41
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Clinical Trials Market, Global, Clinical Trials by Erasmus MC, 2014* 42
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Chicago, 2014* 43
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Louisville, 2014* 44

List of Figures
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Proportion of Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) to Metabolic Disorders Clinical Trials, G7 Countries (%), 2014* 15
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) to Metabolic Disorders Clinical Trials, E7 Countries (%), 2014* 18
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics, Global, Clinical Trials by Phase (%), 2014* 20
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 21
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics, Global, Clinical Trials by Trial Status, 2014* 22
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Clinical Trials, Global, by End Point Status, 2014* 23
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 26
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 27
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 28
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 29
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 30
GlobalData Methodology 73

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

Regulatory Affairs Outsourcing Market (Services: Regulatory Affairs, Clinical Trial Applications and Product Registrations, Regulatory Writing and Publishing, Regulatory Consulting and Legal Representation and Others) - Global Industry Analysis, Size, Sha

Regulatory Affairs Outsourcing Market (Services: Regulatory Affairs, Clinical Trial Applications and Product Registrations, Regulatory Writing and Publishing, Regulatory Consulting and Legal Representation and Others) - Global Industry Analysis, Size, Sha

  • $ 4 795
  • Industry report
  • October 2014
  • by Transparency Market Research

This report on the regulatory affairs outsourcing market studies the current as well as future prospects of the market globally. Regulatory affairs outsourcing is rapidly gaining popularity in the global ...

Proteomics Markets for Research and IVD Applications

Proteomics Markets for Research and IVD Applications

  • $ 4 200
  • Industry report
  • September 2014
  • by Kalorama Information

This Kalorama Information report defines markets and identifies trends for proteomics applications, both in their research use and in IVD. Proteomics is the study of proteins, including the study of the ...

Biologicals in Oncology Drug Pipeline Update 2014

Biologicals in Oncology Drug Pipeline Update 2014

  • $ 3 749
  • Industry report
  • October 2014
  • by Bioseeker

This drug pipeline update covers a wide array of biological drugs, such as: antibodies,proteins, peptides, DNA, RNA and cellular therapies. There are today 908 companies plus partners developing 1784 biological ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.